Navigation Links
Trial seeks 'genetic fingerprint' for predicting drug effectiveness
Date:10/3/2007

CINCINNATIUniversity of Cincinnati (UC) physician-scientists believe identifying a genetic fingerprint could help predict which specific therapies will be most effective for patients with gastric cancer.

Syed Ahmad, MD, is leading a national, phase-2 trial to test the effectiveness of combined chemotherapy and radiation therapy given to patients with gastric cancer before surgery. His team will also collect biological samples in an attempt to obtain genetic data that could be used to formulate targeted therapies.

Previous studies have established that either chemotherapy or radiation therapy after surgery can improve patient survival compared with surgery alone. Overall survival rates, however, remain lowwith 20 to 30 percent of American patients surviving more than five years after treatment.

Everyone agrees that without surgery, gastric cancer in not curable, and numerous studies have shown a benefit to follow-up therapy with either chemotherapy or radiation therapy, says Ahmad, assistant professor of surgery at UC and principal investigator of the trial.

The problem is you cant give both radiation therapy and chemotherapy after surgeryits too toxic and patients cant tolerate it, he says. But you can give it before surgery when patients are healthiest.

This trial addresses what Ahmad calls the future of cancer therapy: targeted drug regimens, based on the characteristics of a patients specific tumor.

His goal is to identify a genetic fingerprint that could help predict whether patients will respond to therapy, and then identify drugs to address the specific molecular characteristics of that patients tumor.

Right now treatment is based on the assumption that site-based cancers are all the same, so every patient who has stage-3 gastric cancer will get the same chemotherapy drugs, Ahmad explains. But the reality is that every cancer has a different expression of hormones, growth factors and genetic factors that must be addressed individually.

The UC-led national team is looking for about 70 patients across the United States with up to stage-3 gastric cancer to participate in the trial.

Prior to surgery, all study participants will have a biopsy to set baseline standards for genetic testing to determine which patients have a complete response to the multi-treatment therapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL-ih-plah-tin, marketed as Eloxatin) for six to eight weeks.

Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown the drug has fewer toxicity complications compared with other therapies.

After six weeks of chemotherapy, the patient will get five consecutive days of three-dimensional, external-beam radiation therapy. Patients will be reevaluated two to three weeks after radiation to determine if they are eligible for surgery. Those who are suitable will have another tissue biopsy after surgery.

Researchers will compare pre- and post-surgery tissue samples to obtain the genetic data necessary to establish associations between molecular markers and drug resistance, with the goal of reducing toxicity associated with chemotherapeutic agents and improving patient survival.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati
Source:Eurekalert

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. NIAID Initiates Trial of Experimental Avian Flu Vaccine
3. International trial of two microbicides begins
4. Bird Brains Show How Trial and Error May Contribute to Learning
5. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
6. HIV vaccine trial breaks ground for future research
7. Roche clinical trial registry and results database launched
8. NIAID begins clinical trial of West Nile virus vaccine
9. EuroVacc 02 HIV Vaccine Trial Begins
10. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
11. Compound might defeat African sleeping sickness, clinical trial beginning this month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... 27, 2017  The global market for clinical ... to a new report from Kalorama Information.  In ... performed to evaluate disease progression, monitor drug treatment ... reasons.  The healthcare market research firm,s report, ... an overview of the medical laboratory industry and ...
(Date:3/27/2017)... March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a ... Executive Officer, Bill Welch , will be presenting ... at 9:00 AM EDT at the Essex House in ... and Chief Scientific Officer, Mark Erlander , Ph.D., ... the conference.   The presentation will be webcast ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Strategic Business Report" report to their offering. ... This report analyzes the Global ... Annual estimates and forecasts are provided for the period 2014 through ... research. The report profiles 25 companies including many ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
Breaking Biology Technology: